Following is a digest of pharmacogenomics journal articles pertaining to hematology/oncology. The SNP•its editorial team selects articles for inclusion based on clinical relevance and scientific validity. Journal articles that are most readily applicable and relevant to practicing clinicians are selected for a SNP•its Study Summary, which discusses findings and clinical implications of a pharmacogenomics study in the context of the larger evidence base.

Article Citation & LinkTypeMonthSNP•its Study Summary
Lunenburg CA et al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. Eur J Cancer. 2016;54:40-8.Review2016-02
Boige V et al. DPYD genotyping to predict adverse events following treatment with flourouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the PETACC-8 randomized clinical trial. JAMA Oncol. 2016 Jan 21 [Epub ahead of print].Cross-Sectional2016-01
Edwards KL et al. Participant views on consent in cancer genetics research: preparing for the precision medicine era. J Community Genet. 2016 Jan 22 [Epub ahead of print].Qualitative2016-01
Deenen MJ et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: A safety and cost analysis. J Clin Oncol. 2016;34:227-34.Prospective Cohort2016-01
Offer SM et al. Is it finally time for a personalized medicine approach for fluorouracil-based therapies? J Clin Oncol. 2016;34:205-7.Commentary2016-01
Lu CY et al. Clinical implication of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab combined with FOLFIRI in the first-line setting. Transl Oncol. 2015;8:474-9.Retrospective Analysis2015-12
Shi Y et al. Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial. Thorac Cancer. 2015;6:785-91.Randomized Controlled Trial2015-11
Goon CP et al. UGT1A1 mediated drug interactions and its clinical relevance. Curr Drug Metab. 2016;17:100-6.Review2015-11
Launay M et al. Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer. Br J Clin Pharmacol. 2016;81:124-30.Prospective Cohort2015-11
Leung HW et al. Association and prediction of severe 5-fluorouracil toxicity with dihydropyrimidine dehydrogenase gene polymorphisms: A meta-analysis. Biomed Rep. 2015;3:879-83.Meta-analysis2015-11
Di Francia R et al. Rational selection of predictive pharmacogenomics test for the fluoropyrimidine/oxaliplatin based therapy. Eur Rev Med Pharmacol Sci. 2015 ;19:4443-54.2015-11
Yazdi MF et al. CYP2D6 genotype and risk of recurrence in tamoxifen treated breast cancer patients. Asian Pac J Cancer Prev. 2015;16:6783-7.Cohort2015-10
Del Re M,et al. Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients. EPMA J. 2015;6:17.Case Series2015-09
Bermejo-Pérez MJ et al. Toxicity associated with capecitabine in patients suffering from dihydropyrimidine dehydrogenase deficiency. Chemotherapy. 2014;60:353-5.Case Report2015-09
Yoshida Y et al. 5-Fluorouracil chemotherapy for dihydropyrimidine dehydrogenase-deficient patients: potential of the dose-escalation method. Anticancer Res. 2015;35:4881-7.Case Report2015-09
Bermejo-Pérez MJ et al. Toxicity associated with capecitabine in patients suffering from dihydropyrimidine dehydrogenase deficiency. Chemotherapy. 2014;60:353-5.Case Report2015-09
Thomas F et al. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio. Clin Pharmacol Ther. 2015 Aug 11 [Epub ahead of print].Observational2015-08
Sugiyama E et al. Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer. 2015;90:307-13Observational2015-08
Khaled SK et al. Influence of absorption, distribution, metabolism, and excretion genomic variants on tacrolimus/sirolimus blood levels and graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22:268-276.Retrospective Cohort2015-08
Abreu MH et al. CYP2D6*4 polymorphism: a new marker of response to hormonotherapy in male breast cancer? Breast. 2015;24:481-6.Prospective Cohort2015-08
Ravegnini G et al. Personalized medicine in gastrointestinal stromal tumor (GIST): clinical implications of the somatic and germline DNA analysis. Int J Mol Sci. 2015;16:15592–608.Review2015-07
Toffoli G et al. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. Int J Cancer. 2015 Jun 23 [Epub ahead of print].Retrospective Cohort2015-06
Küpeli S. Thiopurine S-methyltransferase and methylenetetrahydrofolate reductase polymorphisms in leukemia. Turk J Haematol. 2015;32:184-5.Opinion2015-06
Tanaka Y et al. Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia. Br J Haematol. 2015 Jun 2 [Epub ahead of print].Prospective Cohort2015-06
Falvella FS et al. Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase. Int J Mol Sci. 2015;16:8884–95.Review2015-04
Etienne-Grimaldi M-C et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundam Clin Pharmacol. 2015;29:219-37.Review2015-04
Frank TS et al. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer. Cancer Lett. 2015;363:1-6.Review2015-04
Hiratsuka M et al. Genetic polymorphisms of dihydropyrimidinase in a Japanese patient with capecitabine-induced toxicity. PloS One. 2015;10:e0124818.Case Report2015-04
Berrueco R et al. Outcome and toxicities associated to chemotherapy in children with acute lymphoblastic leukemia and Gilbert syndrome. Usefulness of UGT1A1 mutational screening. Pediatr Blood Cancer. 2015;62:1195-201.Retrospective analysis2015-04
Duffy MJ. Personalized treatment for patients with colorectal cancer: role of biomarkers. Biomark Med. 2015;9:337–47.Review2015-03
Keung Y-K et al. A case of recurrent pancytopenia in a patient with acute promyelocytic leukemia on maintenance chemotherapy and concomitant methyltetrahydrofolate reductase and thiopurine S-methyltransferase mutation - review of literature. J Oncol Pharm Pract. 2015 Mar 18 [Epub ahead of print].Case Report2015-03
Walcott FL et al. Legislation in the genomic era: the Affordable Care Act and genetic testing for cancer risk assessment. Genet Med. 2015 Mar 5 [Epub ahead of print].Commentary2015-03
Zembutsu H. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer. Pharmacogenomics. 2015;16:287–96. Review2015-03
Dhelens C et al. Lethal 5-fluorouracil toxicity in a colorectal patient with severe dihydropyrimidine dehydrogenase (DPD) deficiency. Int J Colorectal Dis. 2015; Mar 22 [Epub ahead of print].Case Report2015-03
Goldstein DA et al. Costs and effectiveness of genomic testing in the management of colorectal cancer. Oncology (Williston Park). 2015;29:175–183.Review2015-03
Etienne-Grimaldi MC et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundam Clin Pharmacol. 2015;29:219-37.Review2015-03
Falvella FS et al. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. Br J Clin Pharmacol. 2015 Mar 7 [Epub ahead of print].Prospective Cohort2015-03
Diouf B et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015;313:815-23.Retrospective cohort analysis2015-02JAMA: Vincristine peripheral neuropathy linked to CEP72 variability 
McLeod H. Precision medicine to improve the risk and benefit of cancer care: genetic factors in vincristine-related neuropathy [editorial]. JAMA. 2015;313:803-4.

Editorial2015-02JAMA: Vincristine peripheral neuropathy linked to CEP72 variability 
Ciccolini J et al. Pharmacogenetics and breast cancer management: current status and perspectives. Expert Opin Drug Metab Toxicol. 2015;11:719-29.Review2015-02
Froehlich TK et al. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer. 2015;136:730-9. Prospective Cohort2015-02
Zhang X et al. Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy. Med Sci Monit. 2015;21:563–69.Retrospective Cohort2015-02
Johnson JA et al. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies. J Natl Cancer Inst. 2015;107.Editorial2015-02
Sugino S et al. Pharmacogenetics of chemotherapy-induced nausea and vomiting. Pharmacogenomics. 2015;16:149–60.Review2015-01
Fong SCM et al. Getting the best out of thiopurine therapy: thiopurine S-methyltransferase and beyond. Biomark Med. 2015;9:51–65.Review2015-01
Pesenti C et al. Germline oncopharmacogenetics, a promising field in cancer therapy. Cell Oncol (Dordr). 2015 Jan 9 [Epub ahead of print].Review2015-01
Binkhorst L et al. Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping. Cancer Treat Rev. 2015 Jan 14 [Epub ahead of print].Review2015-01
Yang JJ et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015 Jan 26 [Epub ahead of print].GWAS2015-01
Iwamoto T et al. Effect of genetic polymorphism of CYP3A5 and CYP2C19, and concomitant use of voriconazole on blood tacrolimus concentration in patients receiving hematopoietic stem cell transplantation. Ther Drug Monit. 2015 Jan 6[Epub ahead of print].Prospective cohort2015-01
Mei L et al. Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev. 2015 Jan 10 [Epub ahead of print].Review2015-01
Abubakar MB et al. The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients. Pharmacogenet Genomics. 2014;24:575–81.Review2014-12
Goricar K et al. Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma. Pharmacogenet Genomics. 2014;24:514–21.Retrospective Cohort2014-12
Lee AM et al. DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147). J Natl Cancer Inst. 2014;106.Retrospective cohort2014-12DPYD and 5-fluorouracil toxicity: Largest study to date supports association
Belen BF et al. Severe myelotoxicity associated with thiopurine S-methyltransferase*3A/*3C polymorphisms in a patient with pediatric leukemia and the effect of steroid therapy. Turk J Haematol. 2014;31:276–85.Case report2014-12
Burnett HF et al. Testing for thiopurine methyltransferase status for safe and effective thiopurine administration: a systematic review of clinical guidance documents. Pharmacogenomics J. 2014;14:493–502.Systematic Review2014-12
Hagleitner MM et al. Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts. PLoS ONE. 2014;9:e115869.Prospective cohort2014-12
Pui C-H. Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia. Front Med. 2014  Dec 15 [Epub ahead of print].Review2014-12
Li Q et al. Influence of DPYD genetic polymorphisms on 5-fluorouracil toxicities in patients with colorectal cancer: a meta-analysis. Gastroenterol Res Pract. 2014;2014:827989.Meta-analysis2014-12
Lu C-Y et al. FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping. Onco Targets Ther. 2014;7:2143–6.Case report2014-12
Karim NA et al. The use of pharmacogenomics for selection of therapy in non-small-cell lung cancer. Clin Med Insights Oncol. 2014;8:139–44.Retrospective cohort2014-12
Ulrich CM et al. Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304). Cancer. 2014;120:3329–37.Genetic association2014-11
Haroun F et al. Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer. Cancer Chemother Pharmacol. 2014 Nov 27 [Epub ahead of print].Retrospective Cohort2014-11
Lennard L et al. Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics. Br J Haematol. 2014 Nov 29 [Epub ahead of print].Retrospective cohort2014-11
Yun F et al. Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer. J Cancer Res Ther. 2014;10 Suppl:C195–200.Prospective cohort2014-11
Minasian L et al. Optimizing dosing of oncology drugs. Clin Pharmacol Ther. 2014;96:572–9.Review2014-11
Eckhoff L et al. Docetaxel-induced neuropathy: A pharmacogenetic case-control study of 150 women with early-stage breast cancer. Acta Oncol. 2014;1–8.Case Control2014-11
Aráoz HV et al. Pharmacogenetic studies in children with acute lymphoblastic leukemia in Argentina. Leuk Lymphoma. 2014 Nov 20 [Epub ahead of print].Prospective Cohort2014-11
Hronová K et al. Pharmacogenetics and immunosuppressive drugs. Expert Rev Clin Pharmacol. 2014;7:821–35.Review2014-11
Dias MM et al. The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. Pharmacogenomics J. 2014;14:424–31.Meta-Analysis2014-11
Kim KP et al. A Phase I Study of UGT1A1 * 28/ * 6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI. Oncology. 2014;88:164–72.Phase 1 Clinical Trial2014-11
Koo D-H et al. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2014 Nov 23 [Epub ahead of print].Retrospective Cohort2014-11
Alvarellos ML et al. PharmGKB summary: gemcitabine pathway. Pharmacogenet Genomics. 2014;24:564–74.Review2014-11
Lennard L et al. Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics. Br J Haematol. 2014 Nov 29 [Epub ahead of print].Retrospective cohort2014-11
Vine J et al. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia. Leuk Lymphoma. 2014;55:2525–31.Retrospective cohort2014-11
Ali MA et al. ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate. Med Oncol. 2014;31:279.Prospective Cohort2014-11
den Hoed MA et al. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenomics J. 2014 Nov 4 [Epub ahead of print].Prospective Cohort2014-11
Roco A et al. Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy? Front Genet. 2014;5:391.Review2014-11
Rangel LBA et al. Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer. Breast Cancer Res Treat. 2014 Nov 14 [Epub ahead of print].Cross-Sectional2014-11
Murdaca G et al. Pharmacogenetics of etanercept: role of TNF-a gene polymorphisms in improving its efficacy. Expert Opin Drug Metab Toxicol. 2014;10:1703–10.Review2014-11
Guillemette C et al. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications. Clin Pharmacol Ther. 2014;96:324–39.Review2014-10
Chantry AS et al. Clinical application, limits and perspectives of pharmacogenetic and pharmacokinetic analysis of anticancer drugs. Ann Biol Clin. 2014;72:527–42.Review2014-10
Robert J et al. On the use of pharmacogenetics in cancer treatment and clinical trials. Eur J Cancer. 2014;50:2532–43.Perspective2014-10
D’Angelo V et al. Pharmacogenetics of methotrexate in pediatric hematological neoplasm treatment: does it need a personalized regimen based on MTHFR polymorphisms? Expert Review of Hematology. 2014;7:517–19.Review2014-10 
Ulrich CM et al. Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304). Cancer. 2014;120:3329–337.Randomized Controlled Trial2014-10
D’Angelo V et al. Pharmacogenetics of methotrexate in pediatric hematological neoplasm treatment: does it need a personalized regimen based on MTHFR polymorphisms? Expert Rev Hematol. 2014;7:517–9.Editorial2014-10
He H-R et al. Association between methylenetetrahydrofolate reductase polymorphisms and the relapse of acute lymphoblastic leukemia: a meta-analysis. The Pharmacogenomics Journal. 2014;14:432–438.Meta-analysis2014-10 
Levinsen M et al. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity. Cancer Chemother Pharmacol. 2014 Oct 28 [Epub ahead of print.Retrospective Cohort2014-10
Sprowl JA et al. Uptake carriers and oncology drug safety. Drug Metab Dispos. 2014;42:611–22.Review2014-10
Rodríguez-Antona C et al. Pharmacogenomic biomarkers for personalized cancer treatment. J Intern Med. 2014 Oct 23 [Epub ahead of print].Review2014-10
Cruz JE et al. The Power of Genes: A Case of Unusually Severe Systemic Toxicity After Localized Hepatic Chemoembolization With Irinotecan-Eluted Microspheres for Metastatic Colon Cancer. Ann Pharmacother. 2014 Sep [Epub ahead of print].Case report2014-09 Understanding pharmacogenomic data in FDA-approved labeling
Yang SK et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014;46:1017-20.Association2014-09 
Ciardiello F et al. Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol. 2014;25:1673–8.Review

2014-09New Position Statements Give Guidance on Personalized Medicine In Cardiology, Oncology
Harada T et al. Clinical usefulness of testing for UDP glucuronosyltransferase 1 family, polypeptide A1 polymorphism prior to the inititation of irinotecan-based chemotherapy. Mol Clin Oncol. 2014;2:737-43.Retrospective cohort2014-09 
Goetz M et al. CYP2D6 Genotype and Tamoxifen: Considerations for Proper Nonprospective Studies. Clin Pharmacol The. 2014;96:141-4.Point/Counterpoint2014-08 
Relling MV et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther. 2014;96:169–74.Guidelines

Dodson C. Knowledge and Attitudes of Oncology Nurses Regarding Pharmacogenomic Testing. Clin J Oncol Nurs. 2014;18:E64–E70.Descriptive 2014-08 
Berry D. CYP2D6 Genotype and Adjuvant Tamoxifen. Clin Pharmacol Ther. 2014;96:138-40. Point/Counterpoint2014-08 
Province M et al. Interpreting the CYP2D6 Results From the International Tamoxifen Pharmacogenetics Consortium. Clin Pharmacol Ther. 2014;96:144-6.  Point/Counterpoint2014-08 
Cuffe S et al. Cancer patients’ acceptance, understanding, and willingness-to-pay for pharmacogenomic testing. Pharmacogenet Genomics. 2014;24:348-55. Survey2014-07 
Erculj N et al. The influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in children with non-Hodgkin malignant lymphoma. Radiol Oncol. 2014;48:289-92.Retrospective cohort2014-07 
Walko CM et al. Personalizing Medicine in Geriatric Oncology. J Clin Oncol. 2014 Jul; [Epub ahead of print].Review


Hall MJ. Conflicted confidence: academic oncologists' views on multiplex pharmacogenomic testing. J Clin Oncol. 2014;32:1290-2.  Editorial2014-06 
Froehlich TK et al. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer. 2014 [Epub ahead of print]. Prospective cohort study2014-06 
Gray SW et al. Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol. 2014;32:1317-23. Survey2014-05 
Hertz DL et al. Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology. Clin Cancer Res. 2014;20:2530-40. Review2014-05 
Dulucq S et al. Pharmacogenetic considerations for acute lymphoblastic leukemia therapies. Expert Opin Drug Metab Toxicol. 2014;10:699-719. Review2014-05 
Papanastasopoulos P et al. Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice. Anticancer Res. 2014;34:1531-5. Review2014-04 
Chouchana L et al. Interindividual variability in TPMT enzyme activity: 10 years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring. Pharmacogenomics. 2014;15:745-57.  Cross-sectional2014-04 
Liu X et al. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J. 2014;14(2):120-9. Meta-Analysis2014-04Irinotecan ADRs predicted by UGT1A1*28 polymorphisms
Hertz DL et al. Pharmacogenetics of Cancer Drugs. Annu Rev Med. 2014 Oct 29 [Epub ahead of print].Review2014-04
Hagleitner MM et al. The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer. Pharmacogenomics J. 2014 Apr;14(2):115-9.Prospective cohort with meta-analysis2014-04 
Johnson GG et al. CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. Blood. 2013;122:4253-8.Cross-sectional2014-03 
Luzzatto L et al. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol. 2014 Feb;164:469-80. Review2014-02